MedTrace Logo

Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients

NCT00436384 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2008-04-16

No results posted yet for this study

Summary

Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. Since transplant recipients are at risk for CMV or have evidence of infection with CMV, they are given an antiviral drug (usually ganciclovir or valganciclovir). Despite this, there are a chance that CMV infection may cause problems in the future. The purpose of this study is to assess how well patients'immune systems responds to the CMV virus, so that in the future it may be possible to predict which patients are at highest risk of CMV.

Conditions

  • Transplant

Interventions

PROCEDURE

Monitoring-blood samples drawn for CMV testing

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Atul Humar, MD · University Health Network, Toronto

  • Deepali Kumar, MD · University Health Network, Toronto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436384 on ClinicalTrials.gov